Consequently, our data revealed that TTYH3 might function as a favorable tumor activator gene for bladder cancer and that the molecular basis underlying the TTYH3 and FGER1 mediated the MAPK signaling, which can be utilized in MAPK-based bladder cancer therapeutics approach and might hold potential clinical targets. Here, TTYH3 is linked to urinary bladder carcinoma.